小児整形外科インプラントの安全性と有効性 (Global POISE)
前向き観察インプラントの安全性と有効性臨床フォローアッププログラム
Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.
Given the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.
Prospective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).
調査の概要
状態
詳細な説明
STUDY PROCEDURES Screening Patients will be screened against basic inclusion/exclusion criteria to see if patients may be appropriate for study participation according to any standard of care assessments available, and where appropriate with the site's REB/IRB screening procedures and local regulatory requirements. If a patient is deemed eligible, data outlined throughout this protocol will be collected, de-identified and entered into a Research Electronic Database Capture (REDCap) system managed at BCCH.
Enrollment Patients will be assigned a sequential, unique study number (subject ID) and de-identified data will be entered in the study database. The center number is designated by the BCCH team for each individual investigational site. The patient number will be in sequential order by the patient screening date starting with 001. Once a patient has been assigned a subject ID, the number will not be reused.
Pre-Operative Procedures Once a patient is identified as eligible for an Implant Safety and Efficacy device report, it will be determined whether that patient is already enrolled in one of the existing condition-specific registries. Should participants be enrolled in a condition-specific registry, demographic data, medical history, preoperative clinical data, including any pre-existing infections at or near the operative site, and data on pre-operative radiographs for the relevant underlying diagnosis will have already been prospectively collected under registry procedures. If a patient has not been previously enrolled in a condition-specific registry, the patient will be offered enrollment in both the condition registry and for the purposes of the Implant Safety and Efficacy device report. Demographic data, medical history, preoperative clinical data and data on pre-operative radiographs for the relevant underlying diagnosis will then be collected retrospectively from the medical record.
Required Data Collection:
Operative details in the source documentation will be collected that provide specific information from the subject's surgery such as surgical approach, complications, and unique device identification (UDI) numbers for the implanted device.
The following data will be collected and entered into the registry:
- Operative data, specific to the technique related to the relevant OrthoPediatrics system/device
- Assessments of any device-related adverse events
- Assessment for other adverse events
- When possible, the UDI number for the device(s) implanted, or information on the device implanted
Follow-up Procedures
Data collected during routine standard of care follow-up visits will be collected as part of this study. The following data will be collected:
- Radiographs obtained during study clinical evaluations to determine bony union, as well as healing or complications
- Device-related adverse events
- Unanticipated device-related serious adverse device effects
- Information on implant removals not related to an adverse event; degree of bony union just prior to implant removal Unscheduled Visits [if or when needed]
The condition-specific registries are designed to capture every visit that occurs, whether scheduled or unscheduled. An unscheduled visit may occur when an adverse event occurs, or when a patient returns outside of the planned interval window. If an unscheduled visit occurs, the following assessments are to be done:
- Assessment of any adverse events related to the device
- Survivorship of the device
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Harpreet Chhina, PhD
- 電話番号:6008 604-875-2000
- メール:hchhina@cw.bc.ca
研究連絡先のバックアップ
- 名前:Bryn Zomar, PhD
- 電話番号:604-875-2359
- メール:bryn.zomar@cw.bc.ca
研究場所
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6H 3N1
- 募集
- BC Children's Hospital
-
コンタクト:
- Emily Schaeffer, PhD
- 電話番号:604-875-2359
- メール:emily.schaeffer@cw.bc.ca
-
主任研究者:
- Anthony Cooper, FRCSC
-
主任研究者:
- Kishore Mulpuri, FRCSC
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Anyone who meets the eligibility criteria and is within the age limits listed in the above sections can participate in this study.
説明
Inclusion Criteria:
- Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly
- Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product
- Informed consent/assent is required
Exclusion Criteria:
- Patients with a demonstrated sensitivity to metals
- Patients with an inability to follow a post-operative regimen
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Longitudinal Observational Group
Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. |
Patient receives a pediatric orthopaedic implant as a part of standard clinical care. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Device related adverse events
時間枠:2 years post implant insertion
|
Determine the frequency and severity of device-related adverse events at device-specific end points. All adverse events will be recorded and followed during the study. The frequency and severity of device related adverse events will be analyzed to ensure the device risk profile has not changed. |
2 years post implant insertion
|
|
Implant survival
時間枠:2 years post implant insertion
|
Determine the implant survival rate at post-operative end-point: (lack of revision) |
2 years post implant insertion
|
|
Implant efficacy
時間枠:2 years post implant insertion
|
Efficacy will be assessed by post-operative clinical and radiographic evaluations at each follow-up end-point to assess bone fixation and/or deformity correction. |
2 years post implant insertion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Numeric pain rating scale (NPRS)
時間枠:2 years post implant insertion
|
The numeric pain rating scale (NPRS) is a subjective, 11-point numerical scale in which respondents self-report their pain on a scale of 0 (no pain at all) to 10 (worst pain imaginable). |
2 years post implant insertion
|
|
LIMB-Q Kids
時間枠:2 years post implant insertion
|
LIMB-Q Kids is a new patient reported outcome measure (PROM) for children with lower limb deformities. |
2 years post implant insertion
|
|
PROMIS
時間枠:2 years post implant insertion
|
The Patient Reported Outcomes Measurement Information System (PROMIS) measures are self-reported and parent-reported. It includes over 300 measures of global, physical, mental, and social health for adults and children in the general population and those living with a chronic condition. Specifically, the PROMIS Global Health will be administered to all patients while the PROMIS Physical Function - Mobility short form will be administered to those with an implant used in a lower extremity and the PROMIS Physical Function - Upper Extremity short form will be administered to those with an implant used in an upper extremity. |
2 years post implant insertion
|
協力者と研究者
協力者
捜査官
- スタディディレクター:Bryn Zomar, PhD、University of British Columbia
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- H21-03076
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。